Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …

To tackle the global TB epidemic effectively, novel treatment strategies are critically needed
to shorten the duration of TB therapy and treat drug-resistant TB. Drug development for TB …

Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III
trials: New technologies and innovative designs | PLOS Medicine Skip to main content …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Highlights•Dose selection for new combination therapy in tuberculosis has remained
empirical.•Novel tools are needed for effective translation of preclinical models to humans.•A …

Tuberculosis now ranks as the leading cause of death in the world due to a single infectious
agent. Current standard of care treatment can achieve very high cure rates for drug-sensitive …

Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be
enabled by improved preclinical approaches that more effectively inform and ensure safe …

Introduction: Tuberculosis (TB) remains the leading cause of death from a curable infectious
disease; drug-resistant TB threatens to dismantle all prior gains in global control. Suboptimal …

Tuberculosis still remains a global health emergency, claiming 1.5 million lives in 2013. The
bacterium responsible for this disease, Mycobacterium tuberculosis (M. tb), has successfully …